The Rudd Report Updates Research on AMDL's Opportunity in the China Pharmaceutical Market
November 29 2006 - 9:00AM
PR Newswire (US)
TUSTIN, Calif., Nov. 29 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), developer and marketer of tests for the early detection
of cancer and other serious diseases, announced today that The Rudd
Report has updated its research on AMDL, highlighting the unique
opportunity AMDL has in the Chinese Pharmaceutical Market. The
report said that China is developing a new and massive middle
class, whose spending power will redefine the Chinese market.
"These working consumers, once the country's poorest, will steadily
climb the income ladder, with the result that hundreds of millions
of households will enter the country's middle class. While some
companies are already focusing on this evolution, many others have
yet to broaden their vision and thus risk missing this extremely
significant opportunity," the Rudd Report says. The estimate is
that by the year 2025, urban middle class households in China will
make up one of the largest consumer markets in the world. Currently
people in Asia spend less than $40 per capita on pharmaceuticals,
compared to $839 in the U.S. and $439 in Europe. This means that,
with the middle class growing, the Asian pharmaceutical industry
easily could sustain double-digit growth annually over the next
decade. It is estimated that Asia's pharmaceutical market size in
2005 was approximately $106.8 billion. Antibiotics, most of which
are locally manufactured generics, are the main therapeutics
consumed in these developing economies. As the higher income
classes expand beyond the largest urban areas into smaller cities,
there will be a significant upturn in pharmaceutical sales, which
will be of considerable benefit to companies such as the Jade
division of AMDL, The Rudd Report says. "Given the importance of
health care to Chinese families, the country's rapidly aging
population, and the challenges facing the public health care
system...private health expenditures by urban Chinese consumers
will grow at a rate of more than 11 percent annually over the next
two decades. This increase in spending will create significant
opportunities for health care providers, insurance companies,
medical equipment manufacturers, and pharmaceutical companies," the
Report concludes. About The Rudd Report: Lauren Rudd, President of
Savannah Capital Management and publisher of The Rudd Report, has
more than three decades of experience in business and financial
research, investment analysis and professional writing. Investment
returns for his money management firm have exceeded the performance
of the S&P 500 Index every year since the company's inception.
Mr. Rudd's newspaper columns about Wall Street are read by an
estimated six million readers daily. The paid-for research report
and the update are available to be viewed at
http://www.ruddreport.com/amdl_main.htm . About AMDL: AMDL, Inc.
(AMEX:ADL), headquartered in Tustin, California, with operations in
Shenzhen, Jaingxi and Jilin China through its wholly owned
subsidiary Jade Pharmaceutical Inc., is an international biopharma
company. AMDL together with Jade engages in the development,
manufacture and marketing of proprietary pharmaceutical and testing
products. More information about AMDL and its products can be
obtained at http://www.amdl.com/. Forward-Looking Statements: This
news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such
statements are subject to certain risks and uncertainties, and
actual circumstances, events or results may differ materially from
those projected in such forward-looking statements. The Company
cautions readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Gary L. Dreher President & CEO (714)
505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President
& CEO of AMDL, Inc., +1-714-505-4460 Web site:
http://www.ruddreport.com/amdl_main.htm Web site:
http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Sep 2023 to Sep 2024